SCHEMBL4925481

SCHEMBL4925481

Cc1ccccc1Nc1ncnc2c1cnn2-c1ccc(N2CCN(C)CC2)cc1

nearest known ligand 0.74

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 7/20 0.74
LMNA P02545 6/20 0.74
NPC1 O15118 2/20 0.73
RAB9A P51151 2/20 0.73
TSHR P16473 2/20 0.73
HTT P42858 1/20 0.73
SMN1; SMN2 Q16637 1/20 0.73
HSD17B10 Q99714 1/20 0.73
MAPT P10636 7/20 0.62
CCNK O75909 2/20 0.54
CCNA2 P20248 2/20 0.54
CDK2 P24941 2/20 0.54
CCND3 P30281 2/20 0.54
CDK9 P50750 2/20 0.54
CDK6 Q00534 2/20 0.54
MAPK14 Q16539 3/20 0.54
GAA P10253 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4924462 0.96 LMNA (0.69) TP53LMNANPC1RAB9ATSHR
SCHEMBL4925776 0.91 LMNA (0.69) TP53LMNANPC1RAB9ATSHR
SCHEMBL4920822 0.91 TP53 (0.64) TP53LMNANPC1RAB9ATSHR
SCHEMBL4925084 0.91 TP53 (0.64) TP53LMNANPC1RAB9ATSHR
SCHEMBL4924582 0.89 TP53 (0.59) TP53LMNANPC1RAB9ATSHR
SCHEMBL4915307 0.89 LMNA (0.74) TP53LMNANPC1RAB9ATSHR
SCHEMBL4929562 0.88 MAPT (0.58) TP53LMNANPC1RAB9ATSHR
SCHEMBL4916727 0.87 LMNA (0.70) TP53LMNANPC1RAB9ATSHR
SCHEMBL4921223 0.87 LMNA (0.62) TP53LMNANPC1RAB9ATSHR
SCHEMBL4921261 0.85 LMNA (1.00) TP53LMNANPC1RAB9ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096868-A1 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors NOVARTIS AG (CH) 2008-04-24 US claimed
EP-1812441-A1 1,4 SUBSTITUTED PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS Novartis AG (CH) 2007-08-01 EP claimed
WO-2006050946-A1 1,4 SUBSTITUTED PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS NOVARTIS AG (CH) 2006-05-18 WO claimed
US-20080096868-A1 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors NOVARTIS AG (CH) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096868-A1 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors MAP3K1, MAP4K2, MAP4K5 TP53 849/4885LMNA 3959/4885NPC1 1579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.